Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

Also called NCT01103414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 356 participants (enrolled count) (from the registry)
Sponsor
Metabolic Solutions Development Company (from the registry)
Registry
  • NCT NCT01103414
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01103414. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-03-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Intervention (Drug)
Mitoglitazone
Intervention (Drug)
Mitoglitazone
Intervention (Drug)
Mitoglitazone
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Placebo
Lead sponsor
Metabolic Solutions Development Company (class: industry)

Record details

Record id
cardio:ct-nct01103414
Content hash
20c36f578a2c33372af853bc7def6b30facd5b05a97c4a6bcd5985c1d89cd07c